11/25
08:01 am
clym
Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
11/25
07:00 am
clym
Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
11/8
01:13 am
clym
11/6
07:01 am
clym
Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates
Low
Report
Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates
11/3
07:00 am
clym
Climb Bio to Present at Upcoming Investor Conferences
Neutral
Report
Climb Bio to Present at Upcoming Investor Conferences
10/21
07:00 am
clym
Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy
Low
Report
Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy
10/17
07:00 am
clym
Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025
Neutral
Report
Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025
10/16
08:08 am
clym
Climb Bio (NASDAQ:CLYM) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $8.00 price target on the stock.
Low
Report
Climb Bio (NASDAQ:CLYM) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $8.00 price target on the stock.
10/16
08:08 am
clym
Climb Bio (NASDAQ:CLYM) is now covered by analysts at William Blair. They set an "outperform" rating on the stock.
Low
Report
Climb Bio (NASDAQ:CLYM) is now covered by analysts at William Blair. They set an "outperform" rating on the stock.
10/14
07:57 am
clym
Climb Bio (NASDAQ:CLYM) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.
Low
Report
Climb Bio (NASDAQ:CLYM) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.
10/13
07:05 am
clym
Climb Bio (NASDAQ:CLYM) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock.
Medium
Report
Climb Bio (NASDAQ:CLYM) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock.
10/6
03:30 am
clym
Medium
Report
10/1
07:47 am
clym
Climb Bio taps Susan Altschuller as CFO [Seeking Alpha]
Low
Report
Climb Bio taps Susan Altschuller as CFO [Seeking Alpha]
10/1
07:13 am
clym
Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer [Yahoo! Finance]
Low
Report
Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer [Yahoo! Finance]
10/1
07:00 am
clym
Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer
Low
Report
Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer
9/30
08:04 am
clym
Climb Bio (NASDAQ:CLYM) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $8.00 price target on the stock, up previously from $7.00.
Neutral
Report
Climb Bio (NASDAQ:CLYM) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $8.00 price target on the stock, up previously from $7.00.
9/29
07:28 am
clym
Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN [Yahoo! Finance]
High
Report
Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN [Yahoo! Finance]
9/29
07:00 am
clym
Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN
Medium
Report
Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN
9/28
03:33 am
clym
9/22
11:02 am
clym
Climb Bio (NASDAQ:CLYM) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $7.00 price target on the stock.
Low
Report
Climb Bio (NASDAQ:CLYM) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $7.00 price target on the stock.
9/20
01:09 am
clym
Low
Report